My Dashboard
Fin. Planning
Our Solutions
Stocks
Funds
Invest in the best stock opportunities right now and every time.
Start Research-backed Investing ...in less than a minute.
BSE: 500124 | NSE: DRREDDY | Pharmaceuticals & Drugs | Large Cap
1. Is Dr. Reddys Laboratories Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Dr. Reddys Laboratories Ltd is a good quality company.
2. Is Dr. Reddys Laboratories Ltd undervalued or overvalued?
The key valuation ratios of Dr. Reddys Laboratories Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Dr. Reddys Laboratories Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Dr. Reddys Laboratories Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘValue Creation Index Colour Code Guide ⓘ |
|||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | |||
| ROCE % ⓘ | 17.7% | 18.1% | 17.8% | 16.5% | 8.1% | 5.8% | 10.7% | 11.5% | 10.1% | 9.4% | - | ||
| Value Creation Index ⓘ | 0.6 | 0.6 | 0.6 | 0.5 | -0.3 | -0.5 | -0.1 | 0.0 | -0.1 | -0.2 | - | ||
Growth Parameters ⓘGrowth Parameters Colour Code Guide ⓘ |
|||||||||||||
| Sales ⓘ | 11,896 | 13,415 | 15,023 | 15,568 | 14,196 | 14,281 | 15,448 | 17,517 | 19,048 | 21,545 | 22,685 | ||
| YoY Gr. Rt. % | - | 12.8% | 12% | 3.6% | -8.8% | 0.6% | 8.2% | 13.4% | 8.7% | 13.1% | - | ||
| Adj EPS ⓘ | 90.7 | 112.8 | 134 | 142.3 | 78.3 | 57.1 | 110.2 | 119.6 | 112.3 | 118.7 | 218.8 | ||
| YoY Gr. Rt. % | - | 24.3% | 18.8% | 6.2% | -45% | -27% | 93% | 8.5% | -6.1% | 5.7% | - | ||
| BVPS (₹) ⓘ | 371 | 457.3 | 572.9 | 731.5 | 734.7 | 752.4 | 840 | 932.3 | 1,052.6 | 1,146 | 1,321.9 | ||
| Adj Net Profit ⓘ | 1,541 | 1,919 | 2,282 | 2,427 | 1,297 | 947 | 1,830 | 1,987 | 1,868 | 1,976 | 3,644 | ||
| Cash Flow from Ops. ⓘ | 1,378 | 1,970 | 2,524 | 3,263 | 2,144 | 1,803 | 2,870 | 2,984 | 3,570 | 2,811 | - | ||
| Debt/CF from Ops. ⓘ | 2.7 | 2.3 | 1.7 | 1 | 2.3 | 2.8 | 1.3 | 0.7 | 0.9 | 1.2 | - | ||
CAGR ⓘCAGR Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 9 Years | 5 Years | 3 Years | 1 Years | |||||||||
| Sales ⓘ | 6.8% | 8.7% | 11.7% | 13.1% | ||||||||
| Adj EPS ⓘ | 3% | 8.7% | 2.5% | 5.7% | ||||||||
| BVPS ⓘ | 13.4 | 9.3 | 10.9 | 8.9 | ||||||||
| Share Price | 9.8% | 16.5% | 17.2% | 7.8% | ||||||||
Key Financial Parameters ⓘPerformance Ratio Colour Code Guide ⓘ |
||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar'13 | Mar'14 | Mar'15 | Mar'16 | Mar'17 | Mar'18 | Mar'19 | Mar'20 | Mar'21 | Mar'22 | TTM | ||
| Return on Equity % ⓘ | 27.1 | 27 | 25.8 | 21.7 | 10.5 | 7.6 | 13.8 | 13.4 | 11.2 | 10.7 | 17.7 | |
| Op. Profit Mgn % ⓘ | 22.9 | 24.2 | 23.4 | 25.8 | 17.5 | 16.5 | 20.6 | 14.1 | 20.3 | 17.5 | 23.1 | |
| Net Profit Mgn % ⓘ | 13 | 14.3 | 15.2 | 15.5 | 8.9 | 6.4 | 11.9 | 11.3 | 9.8 | 9.2 | 16.1 | |
| Debt to Equity ⓘ | 0.6 | 0.6 | 0.4 | 0.3 | 0.4 | 0.4 | 0.3 | 0.1 | 0.2 | 0.2 | - | |
| Working Cap Days ⓘ | 179 | 185 | 187 | 193 | 212 | 222 | 214 | 207 | 213 | 216 | 0 | |
| Cash Conv. Cycle ⓘ | 115 | 116 | 122 | 128 | 140 | 137 | 130 | 126 | 132 | 135 | 0 | |
Return on Equity has increased versus last 3 years average to 17.70%
Sales growth is growing at healthy rate in last 3 years 11.73%
Sales growth is good in last 4 quarters at 12.89%
Net Profit has been subdued in last 3 years 2.52%
| Standalone | Consolidated | |
|---|---|---|
| TTM EPS (₹) | 141.7 | 218.8 |
| TTM Sales (₹ Cr.) | 15,433 | 22,685 |
| BVPS (₹.) ⓘ | 1,175.7 | 1,321.9 |
| Reserves (₹ Cr.) ⓘ | 19,496 | 21,930 |
| P/BV ⓘ | 3.81 | 3.38 |
| PE ⓘ | 31.58 | 20.45 |
| From the Market | |
|---|---|
| 52 Week Low / High (₹) | 3787.55 / 4645.55 |
| All Time Low / High (₹) | 6.25 / 5613.65 |
| Market Cap (₹ Cr.) | 74,538 |
| Equity (₹ Cr.) | 83.3 |
| Face Value (₹) | 5 |
| Industry PE ⓘ | 35.7 |
| Pledged * | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Dr. Reddy’s Laboratories Limited commenced its generics business in India in 1986 and is today a trusted name in the healthcare industry consistently serving the needs of millions of patients with high quality, affordable and innovative medicines across therapy areas. The company’s shares trade on the Bombay Stock Exchange and the National Stock Exchange in India and on the New York Stock Exchange in the United States.
Business area of the company
The company is a leading India-based pharmaceutical company headquartered and having its registered office in Hyderabad, Telangana, India. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the Company offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical Services (CPS), generics, biosimilars and differentiated formulations.
Products
Core Businesses
Pharmaceutical services & active ingredients
Global Generics
Proprietary Products
Awards & Recognitions
Milestones
Download APP
